Evidence map›Paper›PMID 33855870›Full record

ReviewPhysiological genomics2021

Can cilia provide an entry gateway for SARS-CoV-2 to human ciliated cells?

Raghad Buqaileh, Hannah Saternos, Sidney Ley, Arianna Aranda, Kathleen Forero, Wissam A AbouAlaiwi

Open access · greenAbstract readReview
In one paragraph

Review in Physiological genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Interplay between respiratory viruses and cilia in the airways.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  5. Review
  6. Article
  7. iScience · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Raghad BuqailehDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
Hannah SaternosDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
Sidney LeyDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
Arianna ArandaDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
Kathleen ForeroDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
Wissam A AbouAlaiwiDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio.
University of Toledo · US

Funding

Role of muscarinic receptor anatgonist in primary cilia structureR15HL140523 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI ABOUALAIWI, WISSAM · 2018 to 2020
$601k
American Foundation for Pharmaceutical Education (AFPE)American Heart Association (AHA) 19PRE34430055HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) 3R15HL140523-01S1HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) 3R15HL140523-01S2HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) 3R15HL140523-01S3HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R15HL140523NHLBI NIH HHS R15 HL140523
6 · The paper itself

Abstract

A worldwide coronavirus pandemic is in full swing and, at the time of writing, there are only few treatments that have been successful in clinical trials, but no effective antiviral treatment has been approved. Because of its lethality, it is important to understand the current strain's effects and mechanisms not only in the respiratory system but also in other affected organ systems as well. Past coronavirus outbreaks caused by SARS-CoV and MERS-CoV inflicted life-threatening acute kidney injuries (AKI) on their hosts leading to significant mortality rates, which went somewhat overlooked in the face of the severe respiratory effects. Recent evidence has emphasized renal involvement in SARS-CoV-2, stressing that kidneys are damaged in patients with COVID-19. The mechanism by which this virus inflicts AKI is still unclear, but evidence from other coronavirus strains may hold some clues. Two theories exist for the proposed mechanism of AKI:

Indexed as

Virus InternalizationAcute Kidney InjuryAngiotensin-Converting Enzyme 2AnimalsCiliaCOVID-19Host-Pathogen InteractionsHumansKidneySARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2ACE2ciliacorona virusCOVID-19

Identifiers

PMID33855870
PMCPMC8213509
OpenAlexW3153004022

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.